Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dac022280ec96f54c694eb427655932 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3181 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-318 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate |
1998-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2005-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e94a54ab88313bdf2a137306156b207b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_805d4f7a285b53e12e5c97d079bf2b7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a0302739568216fff9e722927caa33 |
publicationDate |
2005-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-6878547-B1 |
titleOfInvention |
Antisense oligonucleotides against tenascin for treating vitiligo |
abstract |
The invention relates to specific, optionally modified oligonucleotides with a length of up to 17 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006025363-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002076161-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010183639-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008182808-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006058256-A1 |
priorityDate |
1997-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |